- Investing Ideas
- South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
Results
8
Companies which are potentially undervalued and in an acceptable financial position.
8 companies
Hugel
Market Cap: ₩2.6t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩240,500.00
7D
-5.7%
1Y
-30.7%
Dong-A Socio Holdings
Market Cap: ₩549.5b
Engages in the pharmaceutical business in South Korea.
A000640
₩82,900.00
7D
0.1%
1Y
-29.7%
Dong-A ST
Market Cap: ₩350.4b
Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.
A170900
₩36,350.00
7D
3.1%
1Y
-24.1%
Daewoong Pharmaceutical
Market Cap: ₩1.5t
Develops, manufactures and commercializes pharmaceutical products in South Korea and internationally.
A069620
₩131,900.00
7D
-0.5%
1Y
-18.3%
PharmaResearch
Market Cap: ₩3.3t
Operates as a biopharmaceutical company primarily in South Korea.
A214450
₩319,500.00
7D
-6.3%
1Y
-43.0%
Hanmi Pharm
Market Cap: ₩4.9t
A biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally.
A128940
₩389,000.00
7D
-15.7%
1Y
36.3%
Medy-Tox
Market Cap: ₩473.8b
Operates as a biopharmaceutical company in South Korea.
A086900
₩72,700.00
7D
-8.1%
1Y
-55.4%
ST PharmLtd
Market Cap: ₩2.6t
Provides manufacturing services for active pharmaceutical ingredient and intermediate.
A237690
₩123,600.00
7D
-5.3%
1Y
48.4%